glp-1 receptor agonist and dpp-4 inhibitor combination contraindicated dpp-4_inhibitors [TUSOM DPP4 Inhibitors vs GLP-1 Agonists
Description
A 4-week phase 1 study investigated CT-996 in participants with BMI 30 kg/m 2 in 3 different cohorts, with target doses of 90 mg and 120 mg (52)
1,2 For this reason, its important to further understand the mechanism of GLP-1 therapies, said Lorenzo Leggio, a neuroendocrinologist at the National Institute on Drug Abuse who mediated the GLP-1 press conference at the 2025 Society for Neuroscience meeting
(5) Black Chokeberry Scientific name Aronia melanocarpa
One of the key features of neuropathic pain is central sensitization, where the CNS becomes hyper-responsive to pain stimuli [105]
A novel anti-inflammatory mechanism
Given the high disease burden of NASH and limited therapeutic options currently available, the FDA has proposed an accelerated pathway for drug approval
